Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 197

Results For "API"

3787 News Found

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
News | July 10, 2024

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies


Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection
News | July 10, 2024

Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection

The Unit has been issued GMP Certification from ANVISA-Brazil


Olverembatinib approved for commercialization in Macau China
Drug Approval | July 09, 2024

Olverembatinib approved for commercialization in Macau China

Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program


Increasing public awareness on World Zoonoses Day
News | July 08, 2024

Increasing public awareness on World Zoonoses Day

India boasts the largest livestock population, with 536 million livestock and 851 million poultry


Viatris closes divestitures of OTC business
News | July 08, 2024

Viatris closes divestitures of OTC business

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth


Nephro Care India lists at 90% premium
News | July 06, 2024

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90


Biogen completes acquisition of HI-Bio
News | July 06, 2024

Biogen completes acquisition of HI-Bio

Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study


FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss
News | July 06, 2024

FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss

Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness


Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform
News | July 05, 2024

Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform

Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization